Hepatic Proteome Analysis of Atlantic Salmon (Salmo salar) After Exposure to Environmental Concentrations of Human Pharmaceuticals by Hampel, Miriam et al.
Hepatic Proteome Analysis of Atlantic Salmon
(Salmo salar) After Exposure to Environmental
Concentrations of Human Pharmaceuticals*□S
Miriam Hampel¶¶‡‡¶, Esteban Alonso§, Irene Aparicio§, Juan Luis Santos§,
and Michael Leaver‡
Pharmaceuticals are pseudopersistent aquatic pollutants
with unknown effects at environmentally relevant concen-
trations. Atlantic salmon (Salmo salar) were exposed to
Acetaminophen: 54.77 34.67; Atenolol: 11.08 7.98, and
Carbamazepine: 7.85  0.13 gL1 for 5 days. After Ac-
etaminophen treatment, 19 proteins were differently ex-
pressed, of which 11 were significant with respect to the
control group (eight up-regulated and three down-regu-
lated). After Atenolol treatment, seven differently ex-
pressed proteins were obtained in comparison with the
control, of which six could be identified (four up-regulated
and two down-regulated). Carbamazepine exposure re-
sulted in 15 differently expressed proteins compared with
the control, with 10 of them identified (seven up-regulated
and three down-regulated). Out of these, three features
were common between Acetaminophen and Carbamaz-
epine and one between Carbamazepine and Atenolol. One
feature was common across all treatments. Principal
component analysis and heat map clustering showed a
clear grouping of the variability caused by the applied
treatments. The obtained data suggest (1) that exposure
to environmentally relevant concentrations of the phar-
maceuticals alters the hepatic protein expression profile
of the Atlantic salmon; and (2) the existence of treatment
specific processes that may be useful for biomarker
development. Molecular & Cellular Proteomics 14: 10.1074/
mcp.M114.045120, 371–381, 2015.
Molecular approaches in ecotoxicology have greatly en-
hanced mechanistic understanding of the impact of aquatic
pollutants in organisms. High throughput “omic” technolo-
gies, including quantitative proteomics methods such as 2D
differential in-gel electrophoresis (DIGE), are now being ac-
knowledged to be a promising tool to evaluate the effects of
contaminant exposure on organisms and are becoming more
widely used in ecotoxicology (1). Information on altered pro-
tein expression, including post-transcriptional modifications,
can provide protein expression signatures, sets of proteins
specific to different stressors, and insight into the possible
mode of action (MoA)1 of chemical pollutants and their higher
level toxicological effects (2–5). Contaminant specific MoAs
and protein expression signatures may be used for monitor-
ization, especially because the use of omic techniques allows
earlier identification of effects than traditional endpoints.
However, ecotoxicoproteomic studies are still relatively un-
common and in their infancy (6).
Human and veterinary pharmaceuticals are being released
into the environment in extremely large quantities on a regular
basis. Millions of prescription and nonprescription drugs are
purchased and ingested by, or applied on individuals every
day and eventually excreted through urine or feces, ultimately
entering the effluent of wastewater treatment plants and
aquatic environments (7). Frequently, sewage treatment does
not affect the chemical structure, and therefore the concen-
trations of drugs that enter aquatic environments can be
sufficient to exert toxicity on nontarget species. Most phar-
maceuticals are relatively stable to avoid being biologically
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inactivated before carrying out their intended biological func-
tion (8). However, this stability means that they also persist
and accumulate in abiotic and biotic compartments of eco-
systems, potentially creating environmental problems (9). In
fact, some major pharmaceutical compounds are now con-
sidered to be included in the priority list of the Water Frame-
work Directive of the European Union (2000/60/EC). The exact
effects that exposure to environmentally relevant concentra-
tions of pharmaceuticals is having on ecosystems, biota, and
also humans who may consume contaminated water or organ-
isms are still not completely understood. Risk assessments
have shown that some pharmaceuticals have the potential to
cause adverse human and environmental effects from indirect
exposure (8, 10–12). For the vast majority however, including
most metabolites, important knowledge gaps still exist concern-
ing long-term effects on nontarget organisms.
Some of the most pervasive groups of pharmaceuticals that
are currently found in aquatic environments are analgesics,
-blockers and anti-epileptics (13–17). In this study, we have
chosen Acetaminophen (APAP; analgesic), Atenolol (AT;
-blocker), and Carbamazepine (CBZ; anti-epileptic) as model
compounds to assess the effects on the liver proteome of
Atlantic salmon, Salmo salar, after exposure to environmen-
tally relevant concentrations. APAP is a non-steroid anti-in-
flammatory and analgesic drug, used as painkiller and to
reduce inflammations and fevers. The exact molecular pro-
cesses are not known yet, and only a limited number of
pathways have been identified (18, 19). Effects of APAP on
gene and protein expression in rodents have been published
elsewhere (20–22). AT is a selective -adrenergic receptor
antagonist or -blocker for the treatment of angina, glau-
coma, heart failure, high blood pressure, and other related
conditions (23–25). An extensive review about the compara-
tive physiology, pharmacology, and toxicology of -blockers,
including AT, in fish has been published recently (26). CBZ is
a mood-stabilizing treatment for bipolar affective disorder.
The molecular mechanisms underlying the actions of CBZ and
the cause of the illness itself are unknown. However, several
biochemical pathways have been postulated as possible tar-
gets of mood stabilizing drugs (27–31).
Salmonids are frequently employed in effects evaluation of
environmental contaminants, and Atlantic salmon are a cul-
turally and economically important sentinel species in many
North-West European rivers. However, wild stocks of Atlantic
salmon are increasingly endangered (32). A variety of ecolog-
ical and climatic reasons for this have been proposed, but
there is little doubt that declines in water quality are a major
threat. The juvenile stages of Atlantic salmon spend a year or
more in rivers, before migrating to the sea, and during these
stages salmon may be particularly vulnerable to contamina-
tion by pharmaceuticals, and other chemicals, especially
when river levels are low. The purpose of this study is to
determine sets of proteins, in the liver of Atlantic salmon parr,
whose expression is changed in response to environmentally
relevant concentrations of APAP, AT, or CBZ. An ontologic
analysis of the salmon proteome associated with pharmaceu-
tical treatment can provide in-depth mechanistic information
of the molecular MoA and the function of the altered proteins.
Furthermore, those proteins that are highly regulated will be
useful as candidates for development as biomarkers in envi-
ronmental monitoring exercises, with potential for indicating
exposure to specific pharmaceuticals, and thus providing an
early indication of the ecological risk posed by pharmaceuti-
cal contaminant discharge.
EXPERIMENTAL PROCEDURES
Ethics Statement—All procedures were performed under license
to, and in accordance with United Kingdom Home Office regulations
governing animal experimentation, and following oversight by an
institutional ethics review committee.
Exposure—APAP (CAS N°: 103-90-2), AT (CAS N°: 29122-68-7),
and CBZ (CAS N°: 298–46-4) were purchased from Sigma. Atlantic
salmon parr (approximately one year old) were purchased from the
Stirling University aquaculture facility (Howietown Fish Farm, Stirling,
UK). The fish were acclimated to laboratory conditions for 14 days.
After that, 15 fish per treatment were exposed to environmentally
relevant concentrations of the pharmaceuticals for 5 days under
continuous flow through conditions. The concentrations were chosen
based on maximum levels detected in various European freshwater
bodies (13–17) and the exposure time of 5 days was selected as an
approximation of low water conditions in a natural riverine environ-
ment. The experiments were carried out in duplicate and control trials
were run simultaneously. A peristaltic pump supplied the compounds
from daily renewed working stock solutions. Water flow through the
system was adjusted to 360 Ld1. Water samples (250 ml) were
collected from each tank at days 1, 3, and 5, and stored at 4 °C not
longer than 24 h until their pretreatment for posterior analysis by high
performance liquid chromatography (HPLC). After 5 days of expo-
sure, all fish were killed by a blow to the head, sexed, and final
weights, tissue weights, and length were measured. Liver tissues
were immediately frozen and stored at 70 °C.
Exposure Concentration Analysis—Exposure concentrations were
measured as described elsewhere (33). After solid phase extraction
(OASIS HLB; 60 mg, 3 ml; Waters, Milford, MA), analytes were sep-
arated under isocratic conditions with acetonitrile and 50 mM potas-
sium dihydrogen phosphate solution. APAP and CBZ were measured
using the UV signal at 250 nm, AT using the fluorescence signal at 271
nm. Compounds were identified and quantified by comparing reten-
tion times and peaks in samples and standard solution chromato-
grams. Limits of detection (LOD) and limits of quantification (LOQ)
were calculated by using a signal-to-noise ratio of 3 and 10,
respectively.
Proteomic Analysis—Frozen liver tissues were homogenized in ly-
sis buffer (7 M urea, 2 M Thiourea, 4% CHAPS, and 30 mM Tris, pH 8.5)
on ice using a glass mortar with pestle for protein solubilization.
Following homogenization, the tissue lysates were centrifuged at
14,000  g for 10 min at 4 °C to remove any insoluble particles. The
supernatant was then transferred into 50 L aliquots and stored at
80 °C until gel electrophoresis was performed. Protein concentra-
tion was determined by the method based on Bradford (Bio-Rad
Protein Assay, Hercules, CA) and adjusted to 5 g L1 by dilution
with lysis buffer. 24 cm long immobilized pH gradient (pH 3–11NL, GE
Healthcare) IPG strips were rehydrated overnight in 450 L DeStreak
with 2.25 L IPG buffer (pH 3–11NL) added (both GE Healthcare).
After rehydration, five individual protein samples (biological repli-
cates; 50 g for each sample) per treatment were labeled with 400
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pmol Cy3 or Cy5 minimal NHS ester dyes (GE Healthcare) allocated
randomly to provide both Cy3 and Cy5 labeled samples for each
treatment. A pool of material from all 20 samples was labeled with
Cy2 (GE Healthcare). Different pairs of Cy3- and Cy5-labeled samples
(randomly allocated and each containing 50 g of protein) were
combined and mixed with a 50-g aliquot of the Cy2-labeled pooled
standard. These mixtures were diluted 1:1 with lysis buffer containing
0.5% IPG buffer (pH 3–10) and then applied onto the IPG strips.
Isoelectric focusing (IEF, first dimension) was carried out on an IPG-
phor system (GE Healthcare) in four stages with a ramped voltage
change between each step: step and hold: 30V, 12 h; gradient 300V,
1 h; step and hold: 300V, 1 h; gradient: 1000V,1 h; step and hold:
1000V, 1 h; gradient: 8000V, 2 h; step and hold: 8000V, 8 h. Focusing
was stopped after a total of 70,000 Vh accumulated. After IEF, the IPG
strips were equilibrated for 15 min in equilibration buffer I (6 M urea,
2% SDS, 0.05 M Tris-Cl at pH 8.8, 50% glycerol, and 2% DTT)
followed by 15 min in equilibration buffer II (same as buffer I but
containing 2.5% iodacetamide instead of DTT and 0.02% bromphe-
nol blue). The second dimensional separations were carried out on
12.5% SDS-polyacrylamide gels on the Ettan DaltSix system (GE
Healthcare) at 1W/gel for one hour and subsequently at 15W/gel.
Image Analysis—Labeled proteins were visualized using the Ty-
phoon 9000 series imager (GE Healthcare) and the Cy2, Cy3, and Cy5
components of each gel were individually imaged using excitation/
emission wavelengths specific for Cy2 (488/520 nm), Cy3 (532/580
nm), and Cy5 (633/670 nm). PMT was varied in order to equalize
fluorescence intensities between channels and to prevent over satu-
ration of the signal. Background subtraction, quantitation, normaliza-
tion, and first-level-of matching (within gel) was performed by Differ-
ential In-gel Analysis (DIA) using DeCyder 2D Differential Analysis
Software v6.5 (GE Healthcare). For each gel, normalized spot volumes
(area multiplied by density of the spot) were calculated as the ratio of
each spot volume to total spot volume in the gel. Within the Biological
Variation Analysis (BVA) module, each drug treatment set was com-
bined, compared with the control treatment set (t test) and spots with
a p value 0.05 returned.
In-gel Digestion and Mass Spectrometry—A preparative gel with
300 g of protein was used for spot picking and visualized with silver
staining to pick spots of interest. The gel pieces were destained and
digested by trypsin (Promega, Madison, WI). Upon concentrating and
desalting tryptic fragments using Millipore C18 ZipTips (Millipore,
Bedford, MA), samples were mixed in a 1:1 ratio with -cyano-4-
hydroxycinnamic acid matrix (saturated solution in 50% ACN and
2.5% TFA) and spotted onto the target plate. MS/MS analyses were
performed on a 4800 MALDI-TOF/TOF instrument (Applied Biosys-
tems, Foster City, CA). Measurements were taken in the positive ion
mode between 900 and 3000 m/z. Sequences were automatically
acquired by scanning first in peptide mass fingerprint (MS) mode. A
database search (NCBI nr) was performed, combining the results of
peptide mass fingerprint (MS) with subsequent fragmentation (MS/
MS) of up to twelve peptides from each spot according to the quality
of the MS spectrum, using MASCOT (Version 2.0.00, release date:
19.02.2007) as a search engine. Scores greater than the given cutoff
value for MS/MS fragmentation data were taken as significant (p 
0.05). Protein lists were submitted to Venn analysis (http://bioinfogp.
cnb.csic.es/tools/venny/) to detect treatment specific and/or com-
mon features.
Data Evaluation by Multivariate Statistical Analyses—Multivariate
analyses were performed on datasets constituted by the relative
levels of all the spots that were consistently matched between the 20
gels, in order to avoid the replacement of null values by inference.
Principal component analysis (PCA) was based on the obtained spots
of interest where hierarchical clustering was performed on all differ-
ently expressed spots. PCA and cluster analysis were carried out
using the DeCyder software package (DeCyder 2D Differential Anal-
ysis Software v6.5; GE Healthcare).
RESULTS
Exposure Concentration—The measured average concen-
trations of the three selected pharmaceuticals were: APAP:
54.77  34.67 gL1; AT: 11.08  7.98 g/L, and CBZ:
7.85  0.13 g/L. All fish survived the 5-day trial.
Protein Expression Analysis—In order to identify sets of
proteins that respond to different pharmaceutical exposure in
Atlantic salmon, we compared the liver proteome of the four
experimental groups (CTRL, APAP, AT, and CBZ) using 2D-
DIGE. One representative gel for each experimental condition
is shown in Fig. 1A–1D. A total of 53 significantly differently
expressed spots were acquired in a reproducible way across
all gels and after statistical analysis (t test, p  0.05) signifi-
cant differences in several spots were detected between the
experimental groups. For the APAP treatment, 19 spots were
differently expressed, of which 11 were significant with re-
spect to the control group. Eight of these 11 spots were
up-regulated, whereas only three were down-regulated. After
AT treatment, seven differently expressed spots were ob-
tained in comparison with the control of which six could be
identified. Four of them were up-regulated and two down-
regulated. CBZ exposure resulted in 15 differently expressed
spots compared with the control, with 10 of them identified. In
this last treatment, seven features were up-regulated and
three down-regulated. Tables I, II, and III show the results of
protein spot identification for the APAP, AT, and CBZ treat-
ment, respectively. The 78kDa glucose regulated protein ob-
served in the AT treatment (Table II) is the feature with the
highest absolute change, down-regulated 2.469-fold. Three
features were common between different treatments (Fig. 2):
the phosphoglycerate kinase 1 (gi 197631857) was up-regu-
lated in all three treatments (APAP: 1.722; AT: 1.307, and
CBZ: 1.754 and 1.491). Two other features were represented
both in the APAP as well as in the CBZ treatment: acetyl-CoA
acetyltransferase, cytosolic (gi 213513638), which was up-
regulated during the APAP treatment 1.412 times and during
the CBZ treatment 1.279 times, and the glyceraldehyde-3-
phosphate dehydrogenase (gi 209737954), which was up-
regulated during the APAP treatment 1.484 times, whereas
during the CBZ treatment it was down-regulated 1.704 times.
Obtained fold changes throughout all the treatments were
relatively low, and absolute values comprised between 1.2
(threshold setting) and 2.5.
Multivariate Analyses—Data were analyzed by two different
multivariate analysis methods using the DeCyder-Extended
Data Analysis (EDA) module. Principal component analysis
(PCA) was applied to visualize the differences in expression
patterns in the different spot maps from treated and untreated
organisms (Fig. 3).
By analyzing the first two PCs a total separation of the
different spot maps into the four different groups is observed,
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with the treatments APAP and CBZ more separated from each
other than the AT and Control group. These latter treatments,
although also clearly separated, show a slight overlap and are
positioned closer to the coordinate intersection than the other
two treatments. The control group was separated from the
rest of the treatments in the first component (PC1) occupying
the most negative position. The rest of the treatments are
more placed toward positive values, with a clear vertical sep-
FIG. 1. Representative 2D DIGE gel
images for the three treatments a)
APAP, b) AT, c) CBZ and d) control.
Each multiplexed gel was charged with
50 g of protein per dye.
TABLE I
Identification of significantly altered proteins after APAP treatment by Mass Fingerprint approach
# Master
spot Putative identification
Homology
to protein
(Genebank)
Protein
scorea
Protein
score
C.I. %
Protein
MW
Protein
PI
Peptide
count
Total
ion
score
Total
ion
C.I. %
T-test
value
Fold
change
556 Transketolase Salmo salar 114 100 68896.6 6.18 15 24 0 0.0151 1.978
gi 213511480
899 ATP synthase H transporting
mitochondrial F1 complex beta
Salmo salar 105 99.998 52910.6 4.87 11 33 56.937 0.0061 1.639
gi 198285477
952 Elongation factor 1-gamma Salmo salar 232 100 34931.8 9.19 11 164 100 0.0081 1.414
gi 213515528
1052 Phosphoglycerate kinase 1 Salmo salar 315 100 44917.1 8.31 11 257 100 0.0004 1.722
gi 197631857
1053 RNA polymerase beta
subunit protein
Rhododendro n Simsii 73 97.18 156861.6 9.05 18 – – 0.0458 1.534
gi 290489550
1061 unknown Arabidopsis thaliana 69 92.582 8922.7 9.3 6 – – 0.0055 1.423
gi 116830485
1122 Acetyl-CoA acetyltransferase,
cytosolic
Salmo salar 243 100 41722 8.07 8 196 100 0.0024 1.412
gi 213513638
1177 OsmC-like family protein Dichelobacter nodosus
VCS1703A
73 97.428 16299 5.22 8 – – 0.0359 1.649
gi 146329847
1284 Glyceraldehyde-3-phosphate
dehydrogenase-1
Salmo salar 468 100 36097.4 7.12 21 238 100 0.0309 1.51
gi 209737954
1408 Caspase-3 Salmo salar 94 99.975 31376.4 5.97 10 – – 0.0109 1.541
gi 213513742
1788 Peptidyl-prolyl cis-trans
isomerase B precursor
Salmo salar 325 100 23993.6 9.18 11 222 100 0.004 1.484
gi 209735348
a Mascot score: Probability Based Mowse Score: Ions score is 10*Log(P), where P is the probability that the observed match is a random
event. Protein scores greater than 83 are significant (p  0.05). MALDI-TOF-TOF peak lists were searched against a NCBInr 10997816 protein
database using MASCOT TM software with the following settings: Type of search: Sequence Query; Enzyme: Trypsin; Fixed modifications:
Carbamidomethyl (C); Variable modifications: Oxidation (M); Mass values: MONOISOTOPIC; Protein Mass: Unrestricted; Peptide Mass
Tolerance:  100 ppm; Fragment Mass Tolerance:  0.2 Da; Max Missed Cleavages: 1; Instrument type: MALDI-TOF-TOF.
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aration (PC2). The second component (PC2) separated the
rest of the experimental groups that were also clustered indi-
vidually, although a slight overlap between the treatments AT
and CBZ could be observed. Also, a pattern analysis gener-
ating a heat map was carried out (Fig. 4) with manual base set
where including those spots that were present in 	 75% of
the spot maps. Unassigned spots were removed and the
applied normalization comprised scaling corresponding to
the subtraction of the internal reference from the control.
This resulted in 1273 spots that were represented in the
heat map. The pattern analysis revealed a hierarchical clus-
tering where the control group and the APAP treatment
showed the most pronounced difference. Control and AT,
as well as APAP and CBZ showed a closer relationship to
each other than to the rest, forming, in both groups, two
separate clusters.
TABLE II
Identification of significantly altered proteins after AT treatment by Mass Fingerprint approach
# Master
spot Putative identification
Homology
to protein
(Genebank)
Protein
score
Protein
score
C.I. %
Protein
MW
Protein
PI
Peptide
count
Total
ion
score
Total
ion
C.I. %
T-test
value
Fold
change
105 Elongation factor 2 Salmo salar 212 100 96406.4 6.19 21 76 99.995 0.0462 1.748
gi 223647986
265 78kDa glucose/regulated
protein Salmo salar
Salmo salar 538 100 72539.3 5 28 288 100 0.0042 2.469
gi 213511032
813 GL16441 Drosophila persimilis 76 98.619 21738.9 10.33 10 – – 0.0121 1.498
gi 195164237
1052 Phosphoglycerate kinase 1 Salmo salar 315 100 44917.1 8.31 11 257 100 0.0002 1.307
gi 197631857
1539 Branched chain amino
acid aminotransferase
Zunongwangia profunda
SM-A87
73 97.244 40105.2 5.63 11 – – 0.0359 1.423
gi 295134966
1782 hypothetical protein Salmo salar 69 92.751 6919.7 9.4 4 29 0 0.0414 1.526
gi 281416447
Mascot score: Probability Based Mowse Score: Ions score is 10*Log(P), where P is the probability that the observed match is a random
event. Protein scores greater than 83 are significant (p  0.05). MALDI-TOF-TOF peak lists were searched against a NCBInr 10997816 protein
database using MASCOT TM software with the following settings: Type of search: Sequence Query; Enzyme: Trypsin; Fixed modifications:
Carbamidomethyl (C); Variable modifications: Oxidation (M); Mass values: MONOISOTOPIC; Protein Mass: Unrestricted; Peptide Mass
Tolerance:  100 ppm; Fragment Mass Tolerance:  0.2 Da; Max Missed Cleavages: 1; Instrument type: MALDI-TOF-TOF.
TABLE III
Identification of significantly altered proteins after CBZ treatment by Mass Fingerprint approach
# Master
spot Putative identification
Homology
to protein
(Genebank)
Protein
score
Protein
score
C.I. %
Protein
MW
Protein
PI
Peptide
count
Total
ion
score
Total
ion
C.I. %
T-test
value
Fold
change
272 Elongation factor 2 Salmo salar
gi 223647986 212 100 96406.4 6.19 21 76 99.995 0.0087 1.644
395 Contactin 1a precursor Danio rerio
gi 136256388 70 94.749 115044.4 6.19 15 – – 0.0168 1.576
404 TenA family transcriptional
activator
Marinomonas sp.
MWYL1
gi 152997829 71 95.632 25638.9 5.16 9 – – 0.0285 1.652
559 Transketolase Salmo salar
gi 213511480 165 100 68896.6 6.18 20 – – 0.0406 1.445
1020 Phosphoglycerate kinase 1 Salmo salar
gi 197631857 315 100 44917.1 8.31 11 257 100 0.0272 1.754
1027 Fumarylacetoacetase Osmerus mordax
gi 225706644 71 95.829 49875.9 6.27 5 53 99.485 0.0211 1.87
1052 Phosphoglycerate kinase 1 Salmo salar
gi 197631857 315 100 44917.1 8.31 11 257 100 0.0272 1.754
1061 unknown Arabidopsis thaliana
gi 116830485 69 92.582 8922.7 9.3 6 – – 0.0281 1.206
1122 Acetyl-CoA acetyltransferase,
cytosolic
Salmo salar
gi 213513638 243 100 41722 8.07 8 196 100 0.0057 1.279
1323 Glyceraldehyde-3-phosphate
dehydrogenase
Salmo salar
gi 209737954 468 100 36097.4 7.12 21 238 100 0.0006 1.704
Mascot score: Probability Based Mowse Score: Ions score is 10*Log(P), where P is the probability that the observed match is a random
event. Protein scores greater than 83 are significant (p  0.05). MALDI-TOF-TOF peak lists were searched against a NCBInr 10997816 protein
database using MASCOT TM software with the following settings: Type of search: Sequence Query; Enzyme: Trypsin; Fixed modifications:
Carbamidomethyl (C); Variable modifications: Oxidation (M); Mass values: MONOISOTOPIC; Protein Mass: Unrestricted; Peptide Mass
Tolerance:  100 ppm; Fragment Mass Tolerance:  0.2 Da; Max Missed Cleavages: 1; Instrument type: MALDI-TOF-TOF.
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DISCUSSION
Because of their wide distribution and pseudo persistence,
an increasing number of studies are focusing on the toxico-
logical effects of exposure to pharmaceuticals in mammalian
(34–37) and fish model species (26, 38–39). To better under-
stand the effects of these potentially hazardous chemicals on
ecologically relevant fish species, the present study aimed at
evaluating the toxicity of short-term exposure to three highly
environmentally prevalent pharmaceuticals in the liver of the
Atlantic salmon parr, Salmo salar, a candidate sentinel spe-
cies. We showed that short-term, subacute exposure to the
three pharmaceuticals induced significant alterations in the
hepatic protein expression profile. To date, effects of expo-
sure to pharmaceuticals at environmentally relevant concen-
trations on nontarget organisms in general and, especially in
Atlantic salmon remain largely unknown. Experiments with
both mammals and teleost fish have shown high 50% lethal
concentration (LC50) values (exposure concentration that pro-
duced mortality in 50% of the exposed organisms), suggest-
ing that acutely exposed animals can tolerate quite high levels
of these pharmaceuticals (40). In the present study, the tested
concentrations were chosen according to environmental lev-
els reported in the literature (13–17) and no mortality was
observed. Using a proteomic analysis as means of evaluation
of low level subacute effects, the present study reported a
number of proteins displaying significant changes in abun-
dance following exposure to the selected pharmaceuticals
and of which most of them were successfully identified and
validated through MASCOT from primary sequence data-
bases using Peptide Mass Fingerprint, sequence query and
MS/MS ion search. The function of these proteins may pro-
vide new clues on the molecular mechanisms by which APAP,
AT, and CBZ induce effects in liver tissue and help to identify
effective biomarkers of this kind of pollutants.
Regarding PCA (Fig. 3), the horizontal distance (PC#1) be-
tween the treated and control group is slightly larger than the
distance between samples within one group, indicating that
the most important difference between groups is because of
the application of different treatments. The vertical distance
(PC#2) between samples in the plot represents biological and
technical variation. Proteins from individual samples were
extracted and processed for each gel, so differences in re-
sistance or sensitivity toward adverse conditions are to be
expected. Additionally, technical variation induced by protein
extraction, labeling, separation, spot picking, and digestion
procedures may also provide a source of variation within a
treatment group. The spot maps with the largest PC#1 values
between each other are those who presented most differ-
ences in expression patterns. These are in our case the maps
from the APAP and the Control treatments, whereas the AT
and CBZ treatment present the least distance and lowest
PC#1 value. This is in concordance with the fact that most
significantly different proteins (this study) and also transcripts
(41) have been found after APAP treatment where the sup-
plied dose was 10 and 5 times higher than the one for CBZ
and AT as found in the environment. Moreover, the target
organ for APAP is the liver, the test tissue employed in this
experiment, whereas the target tissues for AT and CBZ are the
heart and the brain, respectively. Nevertheless, and although
CBZ and AT are not pharmaceutically targeted to liver, these
pharmaceuticals induced changes in hepatic protein expres-
sion in previous studies, such as hepatic cytochrome P450
subfamily members in the case of CBZ (42, 43, 44) or general
hepatic dysfunction in the case of AT (45).
Hierarchical Cluster Analysis result representation as heat
map (Fig. 4) visualizes the pattern of expression of proteins
across treatments as compared with the internal standard.
The trees to the left of the heat map and above the heat map
show the relationships between the proteins and between the
treatments, respectively. Proteins more distantly placed within
branches show greatest differences in expression patterns be-
tween treatments. All three drug treatments varied significantly
from the expression pattern observed in the control (with re-
spect to the internal standard), with the largest difference oc-
curring between the Control and APAP treatment. This is con-
sistent with the PCA, as observed above (Fig. 3).
Expression of Proteins Involved in Energy Metabolism—In
the present study, the proteins transketolase, mitochondrial
ATP synthase, acetyl-CoA acetyltransferase, phosphoglycer-
ate kinase 1, and glyceraldehydes-3-phosphate dehydrogen-
ase were modulated by low level exposure within all the three
treatments. All these enzymes play important roles in energy
metabolism. Several ATP synthase mitochondrial precursors, a
CoA isomerase precursor, as well as several heat shock pro-
teins have also shown to be altered in the liver proteome of
APAP treated mice (21), indicating similar responses in these
FIG. 2. Venn diagram representation of differentially expressed pro-
teins for each treatment in comparison to the control. Individuals were
exposed to 54.77  34.67, 11.08  7.98 and 7.85  0.13 gL1
APAP, AT and CBZ, respectively for 5 days. Venn diagram shows the
overlaps of differentially expressed proteins based on at least a
1.2-fold filter change with a p 
 0.05.
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different vertebrates. However, the doses applied to mice in
these previous experiments were significantly higher that may
explain the higher total number of altered proteins. One of the
first responses of adaptation to stress in fish is the mobilization
of energetic reserves, including the activation of liver glycogen-
olysis and gluconeogenesis in order to maintain a continuous
supply of glucose to essential organs such as brain and muscle
(46). In all three treatments phosphoglycerate kinase 1, an en-
zyme of the gluconeogenic and glycolytic pathways is in-
creased. In APAP glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), another gluconoegenic/glycolytic enzyme is also in-
creased, although this enzyme is decreased in CBZ. Transke-
tolase, important for NADPH production in the pentose phos-
phate shunt, is also increased in APAP and CBZ. At the same
time, we observed a 1.4 and 1.3-fold abundance increase of
acetyl-CoA acetyltransferase in organisms exposed to APAP or
FIG. 3. Principal component analysis (PCA) of the protein spot maps. PC#1 represents the variability because of the applied treatments;
PC#2 represents the variability because of biological and technical variations between samples. The proteins that are included in the PCA were
present in at least 75% of the spot maps and passed the filter of the one-way ANOVA (p  0.01) test.
FIG. 4. Hierarchical cluster analysis. Heat map showing the separation of the different experimental groups taking into account all altered
proteins present in at least 75% of the spot maps and filtered by one-way ANOVA (p  0.01). Every colored box represents a protein that is
up-regulated (red) or down-regulated (green) in a certain treatment. The brighter the color, the more intense is the change.
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CBZ. Acetyl-CoA acetyltransferase is a major enzyme of ketone
body production in liver, and increases suggest responses to
stressors, as well as, gluconeogenesis and, thus, glucose pro-
duction. Overall these results suggest an ametabolic shift from
glycolysis to gluconeogenesis fueled by an increase in NADPH
production and concurrent with up-regulation of the ketogenic
pathway producing metabolic fuel for the liver and peripheral
tissues (47). However, as no significant changes in direct lipid
metabolic enzymes or pathways were observed we did not see
any evidence for mobilization of energy stores. The 1.639-fold
decrease in ATP synthase H transporting mitochondrial F1
complex beta (gi 198285477) protein concentration upon APAP
treatment may indicate mitochondrial toxicity and a loss of
cellular energy production in line with mitochondrial damage.
Previous studies indicated that mitochondrial permeability tran-
sition (MPT) is the principal mechanism in APAP-induced injury,
with a potential to open the transition pore (48). MPT is recently
focused as a mechanism for drug-induced hepatocyte injury (49–
53) and the observed up-regulations of different energy related
features could be a compensatory mechanism. Notably induc-
tion of MPT is a major signal for activation of apoptotic cell
death pathways, and the major executioner of apoptosis,
caspase 3, was also increased after APAP treatment.
Other Proteins—OsmC-like family proteins: in bacteria, this
kind of proteins have shown to be induced by different types
of stress, particularly high osmotic pressure and starvation
(54). The test specimens employed in our experiments were
salmon parr, which were about one month before smoltifica-
tion, still adapted to fresh water. However, undergoing adap-
tation processes may have been already under way as the
process of smoltification implies an adaptation from fresh to
salt water with the accompanying physiological changes re-
quired. It is possible that some osmotic mechanism was
already working in the fish. However, this feature was only
detected in one (APAP) of the three treatments which were
carried out under identical conditions, where its expression
was down-regulated by 1.65 (p 
 0.0359) indicating an inter-
action of APAP with normal osmotic adaptation processes in
the liver.
Elongation factor: In eukaryotes, peptide chain elongation is
mediated by elongation factors EF1 and EF2. EF2, which was
up-regulated in our AT and CBZ treatments, catalyzes the
translocation of peptidyl-tRNA on the ribosome. Elongation
factors are highly conserved among different species and may
be involved in functions other than protein synthesis, such as
organization of the mitotic apparatus, signal transduction,
developmental regulation, aging and transformation (55). EF2
can be modulated by reversible phosphorylation. Increased
levels of phosphorylated EF2 reduce elongation rates pre-
sumably because phosphorylated EF2 fails to bind the ribo-
somes. Treatment of mammalian cells with agents that raise
the cytoplasmic Ca2 and cAMP levels reduce elongation
rates by activating the kinase responsible for phosphorylating
EF2. One of the therapeutic actions of CBZ is a result of its
interaction with the adenylyl cyclase system and the conse-
quent reduction of intracellular cAMP levels (56, 57). Possibly,
at least after the CBZ treatment, the expression of EF2 has
been induced to compensate for the reduction in elongation
rates because of activation of the kinase responsible for phos-
phorylating EF2. In relation to AT, it was shown that beta-
adrenergic receptor blockers can inhibit  adrenoreceptor-
mediated cAMP accumulation in living cardiac rat cells (58).
TenA family transcriptional activator: this protein is a heme
oxygenase related feature that was significantly changed un-
der the CBZ treatment. Effects of CBZ on heme oxidase,
glutathione-S-transferase and cytochrome P450 3A-like have
been observed in the crustacean T. platyurus and the cnidar-
ian H. attenuate, and lipid peroxidation was reduced in both
organisms suggesting redox activity of the lipophilic CBZ
molecule (59). In a related study where we analyzed the ef-
fects of the exposure trials on the liver transcriptome, we
observed altered electron carrier activity and heme binding
activity after CBZ treatment by Blast2Go analysis within the
top 10 GO terms related to molecular function (41). In human,
CBZ is well known to have various hematological toxic ef-
fects, such as aplastic anemia, leukopenia, eosinophilia,
agranulocytosis and thrombocytopenia with often selective
failure of red cell production during CBZ monotherapy (60).
The number of significantly differentially expressed features
we obtained in our three exposure experiments was slightly
lower or at the lower threshold of the average amount found in
proteomic studies carried out in human and rodents (61). In a
study compiling the results from about 200 proteomic exper-
iments in human and rodents, these authors found that a
typical published 2D-based expression proteomics experi-
ment features 400–1500 spots and reports between 10 and
40 identified up- or down-regulated proteins which in many
cases are repeated across the whole range of examined stud-
ies (61). Two features of their top 15 protein list from humans
and rodents were also present in one or more of our identified
protein lists: elongation factors and ATP synthase beta sub-
unit. In relation with the microarray studies carried out within
the same experimental trial, we can observe that tissue sam-
ples from the same individuals have shown to induce far more
features at transcriptome level than at protein level. The num-
ber of differently expressed features per treatment we de-
tected in these experiments was significantly higher (order of
several hundred) than the differently expressed proteins de-
tected in this study (41). Whereas at transcriptome level the
main induced pathways were also those related to energy
metabolism, genes belonging to other processes were al-
tered, in many cases similar to the responses observed in
mammalian studies of similar treatments. These are for in-
stance inflammatory responses after APAP treatment, iron ion
related processes after AT treatment and Ca2 channel ac-
tivity after CBZ treatment. However, when analyzing the same
tissues at protein level, the main effect was alteration of
proteins belonging to energy related processes (41). The si-
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multaneous measurement of thousands of proteins in a cell
has high potential impact in toxicology, as cellular effects and
thus modes of action are more relevant at protein than at
mRNA level. However, as all proteins have different properties
(mass, isoelectric point, solubility, stability, etc.), and may
exist in multiple forms, the accurate measurement of thousands
of proteins in a sample is a very complicated task. Several
approaches have been followed to study the problem of the
complexity of the cellular proteome and the difficulty to isolate
homogeneous samples for this type of studies (62). It is impor-
tant to realize that the relationship between mRNA and protein
content is heavily dependent on time after treatment, cellular
localization as well as stability of the molecules (63).
The lack of obvious congruence in differently expressed fea-
tures after transcriptomic and proteomic analysis, and the re-
sults observed by Petrak et al. (61) that the same proteins seem
to be observed after widely varying treatments, raises the con-
cern that with current proteomic techniques, only the highly
abundant and soluble proteins are detected giving rise to tech-
nical artifacts, limitations or biases of the method. However, the
combination of techniques, transcriptomic and proteomic, of-
fers the opportunity to reliably quantify expression changes and
identify previously unknown features which can be useful tools
in ecotoxicology, if followed by further studies to confirm po-
tential as biomarkers of contaminant specific contamination.
Environmental Relevance—Traditional risk assessment is
based on the derivation of no observed effect concentrations
(NOECs) from laboratory derived dose-response curves for
comparison with measured or estimated exposure concentra-
tions. Although proteomic data does not provide additional
information for the derivation of NOECs, the function of the
altered proteins provides in-depth mechanistic information of
the molecular processes related with the exposure to envi-
ronmental contaminants. In addition, proteins that are found
to be specifically induced by one (group of) contaminant could
be used as a base to develop contaminant specific biomark-
ers for monitoring environmental exposure in wildlife.
It is yet to be determined if the exposure to the selected
concentration ranges would directly produce an adverse re-
sponse, as proteome change alone does not necessarily
equate to toxicity or adversity. An ecologically relevant ad-
verse response is the impairment of functional capacity (mor-
phology, development, lifespan, growth) because of an insult
that exceeds an organism’s homeostatic range and is likely to
have consequences finally at community and ecosystem
level. However, energy used for alteration of the proteome
and metabolic adaptation in response to contamination will
not be available for other critical physiological processes, and
may thus have indirect adverse responses and consequent
knock-on ecosystem effects.
The mass spectrometry proteomics data have been depos-
ited to the ProteomeXchange Consortium (64) via the PRIDE
partner repository with the dataset identifier PXD001354.
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